ClinicalTrials.gg
CompletedNCT03211234Updated Jul 13, 2021Results posted

Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects

A Phase 2 interventional study of 2.0 mg DE-122 Injectable Solution + Lucentis and 4.0 mg DE-122 Injectable Solution + Lucentis in Age-Related Macular Degeneration, sponsored by Santen Inc.. Completed at 14 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-07-13.

Sponsored by Santen Inc. (part of Santen Pharmaceutical Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Enrollment
57th of 124
76 · median 64
Started
2017
with 3 others
Phase 2
24 of 125
1 open now
Registered
109th of 125
by date
Lead sponsor
2 of 125
Santen Inc.

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 57th largest by enrollment of the 124 interventional ones that give a count, is one of 4 that started in 2017, is one of 24 in phase 2, and was the 109th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

To assess the safety and efficacy of repeated intravitreal injections of DE-122 (low dose and high dose) given in combination with Lucentis® in subjects with wet age-related macular degeneration (AMD) compared with Lucentis® alone.

03

Conditions studied

  • Age-Related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide signed written
  • Diagnosis of active choroidal neovascularization secondary to wet AMD
  • BCVA of 65 to 25 ETDRS letters (20/50 to 20/320) in the study eye
  • BCVA of 25 ETDRS letters (20/320) or better in the fellow eye

Exclusion criteria

Exclusion Criteria:

[Ocular]

  • Use or anticipated use of any intravitreal, periocular or photodynamic therapy in the study eye for the treatment of AMD within a specified timeframe prior to Visit 1 and throughout the study
  • Uncontrolled or advanced glaucoma, chronic hypotony or vitrectomy in the study eye
  • Evidence of any other ocular disease other than exudative age-related macular degeneration in the study eye that may confound the outcome of the study
  • Need for ocular surgery in the study eye during the course of the study
  • Presence or history of certain ocular or periocular pathology or conditions that could limit the ability to perform examinations

[Non-ocular]

  • Allergy or to study drug product, fluorescein dye or other study related procedures and medications
  • Current or history of certain systemic conditions, abnormalities or therapies that would render a subject a poor candidate for the study
  • Participation in other drug or device clinical trials within 30 days prior to randomization or planning to participate in other investigational drug or device clinical trials for the duration of the study
  • Females who are pregnant or lactating and females of who are not using adequate precautions and men who do not agree to practice an acceptable method of contraception throughout the course of the study
  • Unable to comply with study procedures or follow-up visits
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    2.0 mg DE-122

    2.0 mg DE-122 and Lucentis ® 0.5 mg

    Drug: 2.0 mg DE-122 Injectable Solution + Lucentis

  • Experimental
    4.0 mg DE-122

    4.0 mg DE-122 and Lucentis ® 0.5 mg

    Drug: 4.0 mg DE-122 Injectable Solution + Lucentis

  • Sham comparator
    Sham

    Sham and Lucentis ® 0.5 mg

    Drug: Lucentis

Interventions

  • Drug2.0 mg DE-122 Injectable Solution + Lucentis

    Drug pages: Carotuximab · Ranibizumab

    Subjects will receive 6 monthly intravitreal injections of low dose DE-122 in the study eye, in combination with Lucentis.

  • Drug4.0 mg DE-122 Injectable Solution + Lucentis

    Drug pages: Carotuximab · Ranibizumab

    Subjects will receive 6 monthly intravitreal injections of high dose DE-122 in the study eye, in combination with Lucentis.

  • DrugLucentis

    Subjects will receive 6 monthly intravitreal injections of Sham in the study eye, in combination with Lucentis.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 24

    BCVA is the primary efficacy variable for this study, and mean change from baseline in BCVA at Week 24 is the primary efficacy endpoint. An increase in the number of letters read correctly means that vision has improved.The lower the number of letters read correctly on the eye chart, the worse the vision.

    Time frame: Week 24

07

Results

Posted Jul 13, 2021

Participant flow

Participant flow — Overall Study
MilestoneSham2.0 mg DE-1224.0 mg DE-122
Started173128
Completed163025
Not completed113

Outcome measures

PrimaryMean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 24

BCVA is the primary efficacy variable for this study, and mean change from baseline in BCVA at Week 24 is the primary efficacy endpoint. An increase in the number of letters read correctly means that vision has improved.The lower the number of letters read correctly on the eye chart, the worse the vision.

Time frame:
Week 24
Reported as:
Mean · letters
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 24
lettersSham2.0 mg DE-1224.0 mg DE-122
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 244.35 ± 8.9370.87 ± 11.485-1.70 ± 10.550

Adverse events

Collected over From Inform consent to the end of the study at week 32.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sham0/17 (0%)1/17 (5.9%)5/17 (29.4%)
2.0 mg DE-1220/31 (0%)1/31 (3.2%)10/31 (32.3%)
4.0 mg DE-1221/28 (3.6%)4/28 (14.3%)10/28 (35.7%)
Most frequent serious events
Most frequent serious events
EventSham2.0 mg DE-1224.0 mg DE-122
PneumoniaInfections and infestations1/171/310/28
Subretinal fluidEye disorders0/170/311/28
Cardiac arrestCardiac disorders0/170/311/28
OsteoarthritisMusculoskeletal and connective tissue disorders0/170/311/28
AsthmaRespiratory, thoracic and mediastinal disorders0/170/311/28
CataractEye disorders0/171/310/28
Most frequent other events
Showing 10 of 19
Most frequent other events
EventSham2.0 mg DE-1224.0 mg DE-122
Conjunctival hyperaemiaEye disorders0/172/314/28
Eye painEye disorders0/174/311/28
Conjunctival haemorrhageEye disorders2/173/310/28
Retinal haemorrhageEye disorders0/173/313/28
Eyelid oedemaEye disorders0/171/313/28
Conjunctival oedemaEye disorders0/171/312/28
Erythema of eyelidEye disorders0/171/312/28
Visual impairmentEye disorders0/171/312/28
HeadacheNervous system disorders0/170/312/28
Intraocular pressure increasedInvestigations0/172/311/28

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sham2.0 mg DE-1224.0 mg DE-122Total
Mean75.4 ± 9.1872.1 ± 7.3475.6 ± 9.8474.1 ± 8.79
Sex: Female, Male
Sex: Female, Male(Participants)Sham2.0 mg DE-1224.0 mg DE-122Total
Female12141541
Male5171335
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sham2.0 mg DE-1224.0 mg DE-122Total
American Indian or Alaska Native0000
Asian99422
Native Hawaiian or Other Pacific Islander0101
Black or African American0101
White8202452
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Sham2.0 mg DE-1224.0 mg DE-122Total
United States9222556
Philippines89320
08

Study locations

14 sites
  • Retina Research Institute
    Gilbert, Arizona 85296, United States
  • Retina-Vitreous Associates
    Beverly Hills, California 90211, United States
  • Northern California Retina Vitreous Associates
    Mountain View, California 94040, United States
  • Bay Area Retina Associates
    Walnut Creek, California 94598, United States
  • Colorado Retina Associates
    Golden, Colorado 80401, United States
  • National Ophthalmic Research Institute
    Fort Myers, Florida 33912, United States
  • Black Hills Regional Eye Institute
    Rapid City, South Dakota 57701, United States
  • Retina Reseach Center
    Austin, Texas 78705, United States
  • Retina Consultants of Houston
    Houston, Texas 77030, United States
  • Valley Retina Insititute
    McAllen, Texas 78503, United States
  • Asian Eye Institute
    Makati City, Philippines
  • Peregrine Eye and Laser Institute
    Makati City, Philippines
  • The Medical City
    Pasig City, Philippines
  • St. Luke's Medical center Quezon City
    Quezon City, Philippines
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Dec 2019, 29 months.

Results were first posted in Jul 2021, 1 year 6 months after primary completion. A results delay was requested in Sep 2020.

Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 29 months is above that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2017
First posted
Jul 7, 2017
StartActual
Jul 5, 2017
Primary completionActual
Dec 31, 2019
CompletionActual
Jan 31, 2020
Results delay requested
Sep 28, 2020
Results first posted
Jul 13, 2021
Last update
Jul 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03211234
Lead sponsor
Santen Inc.
Responsible party
Sponsor
First posted
Jul 7, 2017
Start date
Jul 5, 2017
Primary completion
Dec 31, 2019
Completion
Jan 31, 2020
Results posted
Jul 13, 2021
Last update
Jul 13, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carotuximab · Ranibizumab

Start the discussion